Based on our analysis of The Cancer Genome Atlas (TCGA) RNAseq database of ovarian serous cystadenocarcinoma we hypothesized that expression of CD44 variants which include variable exons V8, V9, V10, the “epithelial” CD44 isoform, correlate with improved prognosis in ovarian serous cystadenocarcinoma. This evidence concerns the gene CD44 and ovarian serous cystadenocarcinoma.